Analysts have been eager to weigh in on the Healthcare sector with new ratings on Connect Biopharma Holdings (CNTB – Research Report), Aethlon Medical (AEMD – Research Report) and Aclaris Therapeutics (ACRS – Research Report).
Connect Biopharma Holdings (CNTB)
H.C. Wainwright analyst Emily Bodnar initiated coverage with a Buy rating on Connect Biopharma Holdings today and set a price target of $7.00. The company’s shares closed last Friday at $1.18.
According to TipRanks.com, Bodnar is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings with a $7.00 average price target.
See today’s best-performing stocks on TipRanks >>
Aethlon Medical (AEMD)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aethlon Medical, with a price target of $10.00. The company’s shares closed last Friday at $1.74, close to its 52-week low of $1.40.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Aethlon Medical has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
Aclaris Therapeutics (ACRS)
H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Aclaris Therapeutics today. The company’s shares closed last Friday at $1.24, close to its 52-week low of $0.59.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Currently, the analyst consensus on Aclaris Therapeutics is a Hold with an average price target of $1.33, a 9.9% upside from current levels. In a report issued on February 27, Leerink Partners also reiterated a Hold rating on the stock with a $2.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CNTB:
